Lipella Pharmaceuticals (LIPO) Stock Forecast, Price Target & Predictions
LIPO Stock Forecast
Lipella Pharmaceuticals stock forecast is as follows: an average price target of $2.00 (represents a 489.28% upside from LIPO’s last price of $0.34) and
LIPO Price Target
Lipella Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 09, 2024 | Jason McCarthy | Maxim Group | $2.00 | $0.70 | 183.93% | 489.28% |
The latest Lipella Pharmaceuticals stock forecast, released on Apr 09, 2024 by Jason McCarthy from Maxim Group, set a price target of $2.00, which represents a 183.93% increase from the stock price at the time of the forecast ($0.70), and a 489.28% increase from LIPO last price ($0.34).
Lipella Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $2.00 |
| Last Closing Price | $0.34 | $0.34 | $0.34 |
| Upside/Downside | -100.00% | -100.00% | 489.28% |
In the current month, the average price target of Lipella Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Lipella Pharmaceuticals's last price of $0.34. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Lipella Pharmaceuticals Financial Forecast
Lipella Pharmaceuticals Revenue Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|
| Revenue | - | - | - | - |
| Avg Forecast | $142.50M | $139.43M | $136.00K | $146.00K |
| High Forecast | $142.50M | $139.43M | $136.00K | $146.00K |
| Low Forecast | $142.50M | $139.43M | $136.00K | $146.00K |
| # Analysts | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - |
Lipella Pharmaceuticals's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. LIPO's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Lipella Pharmaceuticals EBITDA Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - |
| Avg Forecast | $-89.30M | $-87.38M | $-85.22K | $-91.49K |
| High Forecast | $-89.30M | $-87.38M | $-85.22K | $-91.49K |
| Low Forecast | $-89.30M | $-87.38M | $-85.22K | $-91.49K |
| Surprise % | - | - | - | - |
undefined analysts predict LIPO's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Lipella Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.
Lipella Pharmaceuticals Net Income Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - |
| Avg Forecast | $-1.06M | $-912.68K | $-912.68K | $-1.22M |
| High Forecast | $-1.06M | $-912.68K | $-912.68K | $-1.22M |
| Low Forecast | $-1.06M | $-912.68K | $-912.68K | $-1.22M |
| Surprise % | - | - | - | - |
Lipella Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. LIPO's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Lipella Pharmaceuticals SG&A Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - |
| Avg Forecast | $254.51M | $249.03M | $242.90K | $260.76K |
| High Forecast | $254.51M | $249.03M | $242.90K | $260.76K |
| Low Forecast | $254.51M | $249.03M | $242.90K | $260.76K |
| Surprise % | - | - | - | - |
Lipella Pharmaceuticals's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to LIPO last annual SG&A of $NaN (undefined).
Lipella Pharmaceuticals EPS Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - |
| Avg Forecast | $-0.14 | $-0.12 | $-0.12 | $-0.16 |
| High Forecast | $-0.14 | $-0.12 | $-0.12 | $-0.16 |
| Low Forecast | $-0.14 | $-0.12 | $-0.12 | $-0.16 |
| Surprise % | - | - | - | - |
According to undefined Wall Street analysts, Lipella Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to LIPO previous annual EPS of $NaN (undefined).
Lipella Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| LIPO | Lipella Pharmaceuticals | $0.34 | $2.00 | 488.24% | - |
| FENC | Fennec Pharmaceuticals | $4.65 | $15.75 | 238.71% | Buy |
| ANEB | Anebulo Pharmaceuticals | $1.89 | $6.00 | 217.46% | Buy |
| ACRV | Acrivon Therapeutics | $7.85 | $22.00 | 180.25% | Buy |
| ELYM | Eliem Therapeutics | $5.11 | $13.00 | 154.40% | Buy |
| CELC | Celcuity | $15.36 | $31.50 | 105.08% | Buy |
| ELVN | Enliven Therapeutics | $27.65 | $35.50 | 28.39% | Buy |
LIPO Forecast FAQ
Will Lipella Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for LIPO stock, the company can go up by 489.28% (from the last price of $0.339 to the average price target of $2), up by 489.28% based on the highest stock price target, and up by 489.28% based on the lowest stock price target.
Can Lipella Pharmaceuticals stock reach $1?
LIPO's average twelve months analyst stock price target of $2 supports the claim that Lipella Pharmaceuticals can reach $1 in the near future.
What are Lipella Pharmaceuticals's analysts' financial forecasts?
LIPO's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $282.22M (high $282.22M, low $282.22M), average EBITDA is $-177M (high $-177M, low $-177M), average net income is $-4.107M (high $-4.107M, low $-4.107M), average SG&A $504.05M (high $504.05M, low $504.05M), and average EPS is $-0.54 (high $-0.54, low $-0.54).